Published in J Exp Med on July 01, 1982
Antibodies in malarial sera to parasite antigens in the membrane of erythrocytes infected with early asexual stages of Plasmodium falciparum. J Exp Med (1984) 3.49
Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med (1983) 3.07
Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med (1993) 2.60
A microscale human liver platform that supports the hepatic stages of Plasmodium falciparum and vivax. Cell Host Microbe (2013) 1.95
Genetic control of the immune response in mice to a Plasmodium falciparum sporozoite vaccine. Widespread nonresponsiveness to single malaria T epitope in highly repetitive vaccine. J Exp Med (1986) 1.89
The Plasmodium circumsporozoite protein is proteolytically processed during cell invasion. J Exp Med (2005) 1.85
Monoclonal antibodies identify the protective antigens of sporozoites of Plasmodium knowlesi. Proc Natl Acad Sci U S A (1982) 1.82
Structural and functional properties of region II-plus of the malaria circumsporozoite protein. J Exp Med (1994) 1.75
Immunological mechanisms underlying protection mediated by RTS,S: a review of the available data. Malar J (2009) 1.72
Preerythrocytic, live-attenuated Plasmodium falciparum vaccine candidates by design. Proc Natl Acad Sci U S A (2009) 1.72
Gamma delta T cells contribute to immunity against the liver stages of malaria in alpha beta T-cell-deficient mice. Proc Natl Acad Sci U S A (1994) 1.68
Surface proteins of Plasmodium falciparum merozoites binding to the erythrocyte receptor, glycophorin. J Exp Med (1984) 1.61
Circumsporozoite protein genes of malaria parasites (Plasmodium spp.): evidence for positive selection on immunogenic regions. Genetics (1991) 1.60
The binding of the circumsporozoite protein to cell surface heparan sulfate proteoglycans is required for plasmodium sporozoite attachment to target cells. J Biol Chem (2001) 1.52
Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion. Proc Natl Acad Sci U S A (1986) 1.51
Antigenic diversity and immune evasion by malaria parasites. Clin Diagn Lab Immunol (2004) 1.39
Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccine. J Exp Med (1987) 1.35
A multidomain adhesion protein family expressed in Plasmodium falciparum is essential for transmission to the mosquito. J Exp Med (2004) 1.33
Anopheles stephensi salivary glands bear receptors for region I of the circumsporozoite protein of Plasmodium falciparum. Mol Biochem Parasitol (1997) 1.23
Rapid clearance of malaria circumsporozoite protein (CS) by hepatocytes. J Exp Med (1994) 1.22
Immunity to malaria elicited by hybrid hepatitis B virus core particles carrying circumsporozoite protein epitopes. J Exp Med (1994) 1.20
Development of immunity in natural Plasmodium falciparum malaria: antibodies to the falciparum sporozoite vaccine 1 antigen (R32tet32). J Clin Microbiol (1987) 1.18
A blood stage antigen of Plasmodium falciparum shares determinants with the sporozoite coat protein. Proc Natl Acad Sci U S A (1985) 1.17
Remnant lipoproteins inhibit malaria sporozoite invasion of hepatocytes. J Exp Med (1996) 1.17
Replacing adenoviral vector HVR1 with a malaria B cell epitope improves immunogenicity and circumvents preexisting immunity to adenovirus in mice. J Clin Invest (2010) 1.12
Detection of human antibodies against Plasmodium falciparum sporozoites using synthetic peptides. J Clin Microbiol (1987) 1.10
Monoclonal antibody identifies circumsporozoite protein of Plasmodium malariae and detects a common epitope on Plasmodium brasilianum sporozoites. Infect Immun (1984) 1.09
Monoclonal antibodies produced against sporozoites of the human parasite Plasmodium malariae abolish infectivity of sporozoites of the simian parasite Plasmodium brasilianum. Infect Immun (1985) 1.03
Malaria circumsporozoite protein inhibits protein synthesis in mammalian cells. EMBO J (1998) 1.03
Liposomes, lipid A, and aluminum hydroxide enhance the immune response to a synthetic malaria sporozoite antigen. Infect Immun (1988) 1.03
Immunological markers of Plasmodium vivax exposure and immunity: a systematic review and meta-analysis. BMC Med (2014) 1.02
Mapping the active site of CD59. J Exp Med (1997) 1.02
Molecular dissection of the human antibody response to the structural repeat epitope of Plasmodium falciparum sporozoite from a protected donor. Malar J (2004) 1.01
Inhibitory monoclonal antibody against a (myristylated) small-molecular-weight antigen from Plasmodium falciparum associated with the parasitophorous vacuole membrane. Infect Immun (1988) 1.01
A role for immune responses against non-CS components in the cross-species protection induced by immunization with irradiated malaria sporozoites. PLoS One (2009) 1.01
Class II-restricted protective immunity induced by malaria sporozoites. Infect Immun (2007) 1.00
Induction of humoral immune response against Plasmodium falciparum sporozoites by immunization with a synthetic peptide mimotope whose sequence was derived from screening a filamentous phage epitope library. Infect Immun (1995) 1.00
A linear peptide containing minimal T- and B-cell epitopes of Plasmodium falciparum circumsporozoite protein elicits protection against transgenic sporozoite challenge. Infect Immun (2006) 1.00
A modified hepatitis B virus core particle containing multiple epitopes of the Plasmodium falciparum circumsporozoite protein provides a highly immunogenic malaria vaccine in preclinical analyses in rodent and primate hosts. Infect Immun (2002) 0.97
Role for the Plasmodium sporozoite-specific transmembrane protein S6 in parasite motility and efficient malaria transmission. Cell Microbiol (2008) 0.96
Sporozoite immunization of human volunteers under chemoprophylaxis induces functional antibodies against pre-erythrocytic stages of Plasmodium falciparum. Malar J (2014) 0.95
Enhanced immunogenicity of Plasmodium falciparum peptide vaccines using a topical adjuvant containing a potent synthetic Toll-like receptor 7 agonist, imiquimod. Infect Immun (2008) 0.95
Disruption of the Plasmodium falciparum liver-stage antigen-1 locus causes a differentiation defect in late liver-stage parasites. Cell Microbiol (2011) 0.94
Phase I trial of an alhydrogel adjuvanted hepatitis B core virus-like particle containing epitopes of Plasmodium falciparum circumsporozoite protein. PLoS One (2008) 0.93
Development of a chimeric Plasmodium berghei strain expressing the repeat region of the P. vivax circumsporozoite protein for in vivo evaluation of vaccine efficacy. Infect Immun (2013) 0.93
Adenovirus particles that display the Plasmodium falciparum circumsporozoite protein NANP repeat induce sporozoite-neutralizing antibodies in mice. Vaccine (2011) 0.92
Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc Natl Acad Sci U S A (2014) 0.91
Dual interaction of the malaria circumsporozoite protein with the low density lipoprotein receptor-related protein (LRP) and heparan sulfate proteoglycans. J Exp Med (1996) 0.90
Antibody and B cell responses to Plasmodium sporozoites. Front Microbiol (2014) 0.88
Recombinant peptide replicates immunogenicity of synthetic linear peptide chimera for use as pre-erythrocytic stage malaria vaccine. Microbes Infect (2008) 0.87
Evidence for multiple B- and T-cell epitopes in Plasmodium falciparum liver-stage antigen 3. Infect Immun (2009) 0.86
Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents. Infect Immun (2013) 0.86
Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am J Trop Med Hyg (2011) 0.85
Protective humoral immunity elicited by a needle-free malaria vaccine comprised of a chimeric Plasmodium falciparum circumsporozoite protein and a Toll-like receptor 5 agonist, flagellin. Infect Immun (2013) 0.85
Predicted conformations for the immunodominant region of the circumsporozoite protein of the human malaria parasite Plasmodium falciparum. Proc Natl Acad Sci U S A (1986) 0.84
Circumsporozoite protein of the human malaria parasite Plasmodium ovale identified with monoclonal antibodies. Infect Immun (1988) 0.84
Reversible Conformational Change in the Plasmodium falciparum Circumsporozoite Protein Masks Its Adhesion Domains. Infect Immun (2015) 0.83
A hybrid multistage protein vaccine induces protective immunity against murine malaria. Infect Immun (2012) 0.81
A replicating adenovirus capsid display recombinant elicits antibodies against Plasmodium falciparum sporozoites in Aotus nancymaae monkeys. Infect Immun (2014) 0.81
Malaria vaccines: identifying Plasmodium falciparum liver-stage targets. Front Microbiol (2015) 0.81
Plasmodium falciparum synthetic LbL microparticle vaccine elicits protective neutralizing antibody and parasite-specific cellular immune responses. Vaccine (2013) 0.80
Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin. Clin Vaccine Immunol (2013) 0.79
Fusion of antigen to a dendritic cell targeting chemokine combined with adjuvant yields a malaria DNA vaccine with enhanced protective capabilities. PLoS One (2014) 0.78
Stage-specific and species-specific antigens of Plasmodium vivax and Plasmodium ovale defined by monoclonal antibodies. Infect Immun (1986) 0.78
Ribosome display of combinatorial antibody libraries derived from mice immunized with heat-killed Xylella fastidiosa and the selection of MopB-specific single-chain antibodies. Appl Environ Microbiol (2012) 0.77
Flow Cytometry Based Detection and Isolation of Plasmodium falciparum Liver Stages In Vitro. PLoS One (2015) 0.77
An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses. PLoS One (2014) 0.77
Pre-erythrocytic stage malaria parasites: non-circumsporozoite protein antigens. Bull World Health Organ (1990) 0.77
A slot blot immunoassay for quantitative detection of Plasmodium falciparum circumsporozoite protein in mosquito midgut oocyst. PLoS One (2014) 0.77
Isolation of three distinct parasite populations expressing different circumsporozoite proteins from the Philippine strain of Plasmodium knowlesi. J Clin Microbiol (1988) 0.75
Skin scarification with Plasmodium falciparum peptide vaccine using synthetic TLR agonists as adjuvants elicits malaria sporozoite neutralizing immunity. Sci Rep (2016) 0.75
Force spectroscopy of the Plasmodium falciparum vaccine candidate circumsporozoite protein suggests a mechanically pliable repeat region. J Biol Chem (2016) 0.75
Circumsporozoite protein as a potential target for antimalarials. Expert Rev Anti Infect Ther (2015) 0.75
[The ELISA technic in the screening of mosquitoes infected with Plasmodium falciparum]. Bull World Health Organ (1988) 0.75
A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII. Vaccine (2017) 0.75
Protein O-fucosylation in Plasmodium falciparum ensures efficient infection of mosquito and vertebrate hosts. Nat Commun (2017) 0.75
Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature (1970) 1528.65
Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 83.56
Rapid isolation of antigens from cells with a staphylococcal protein A-antibody adsorbent: parameters of the interaction of antibody-antigen complexes with protein A. J Immunol (1975) 47.77
Fusion between immunoglobulin-secreting and nonsecreting myeloma cell lines. Eur J Immunol (1976) 7.64
ENZYMATIC DIGESTION OF RABBIT GAMMA GLOBULIN AND ANTIBODY AND CHROMATOGRAPHY OF DIGESTION PRODUCTS. Methods Med Res (1964) 6.44
Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med (1980) 4.81
Immunization of man against sporozite-induced falciparum malaria. Am J Med Sci (1973) 4.18
Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. V. In vitro effects of immune serum on sporozoites. Mil Med (1969) 3.37
Protective immunity produced by the injection of x-irradiated sporozoites of Plasmodium berghei. IV. Dose response, specificity and humoral immunity. Mil Med (1969) 2.27
Increased nonspecific resstance to malaria produced by administration of killed Corynebacterium parvum. Exp Parasitol (1967) 2.06
Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med (1981) 2.02
Specificity of protection of man immunized against sporozoite-induced falciparum malaria. Am J Med Sci (1973) 1.84
Antibodies to the protective antigen of Plasmodium berghei sporozoites prevent entry into cultured cells. J Immunol (1982) 1.63
Plasmodium vivax: correlation of circumsporozoite precipitation (CSP) reaction with sporozoite-induced protective immunity in man. Exp Parasitol (1977) 1.59
The protective antigen of malarial sporozoites (Plasmodium berghei) is a differentiation antigen. J Immunol (1981) 1.45
Characterization of sporozoite surface antigens by indirect immunofluorescence: detection of stage- and species-specific antimalarial antibodies. Bull World Health Organ (1979) 1.20
A population of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. I. Separation and characterization. J Exp Med (1970) 15.86
Receptors for complement of leukocytes. J Exp Med (1968) 11.57
Binding of sheep red blood cells to a large population of human lymphocytes. Nature (1971) 7.67
The role of membrane receptors for C3b and C3d in phagocytosis. J Exp Med (1977) 6.19
Phagocytosis of immune complexes by macrophages. Different roles of the macrophage receptor sites for complement (C3) and for immunoglobulin (IgG). J Exp Med (1972) 6.13
Protective immunity produced by the injection of x-irradiated sporozoites of plasmodium berghei. Nature (1967) 6.08
Gamma interferon, CD8+ T cells and antibodies required for immunity to malaria sporozoites. Nature (1988) 5.99
Inhibition of complement activation on the surface of cells after incorporation of decay-accelerating factor (DAF) into their membranes. J Exp Med (1984) 5.47
Enhanced binding of neuraminidase-treated sheep erythrocytes to human T lymphocytes. Blood (1973) 4.99
Complement receptor (CR1) deficiency in erythrocytes from patients with systemic lupus erythematosus. J Exp Med (1982) 4.96
Monovalent fragments (Fab) of monoclonal antibodies to a sporozoite surface antigen (Pb44) protect mice against malarial infection. J Exp Med (1980) 4.81
TRAP is necessary for gliding motility and infectivity of plasmodium sporozoites. Cell (1997) 4.65
Genetic selection of a Plasmodium-refractory strain of the malaria vector Anopheles gambiae. Science (1986) 4.40
Cloned cytotoxic T cells recognize an epitope in the circumsporozoite protein and protect against malaria. Nature (1989) 4.08
A new complement function: solubilization of antigen-antibody aggregates. Proc Natl Acad Sci U S A (1975) 3.97
The evolution of primate malaria parasites based on the gene encoding cytochrome b from the linear mitochondrial genome. Proc Natl Acad Sci U S A (1998) 3.93
Migration of Plasmodium sporozoites through cells before infection. Science (2001) 3.89
Hybridoma produces protective antibodies directed against the sporozoite stage of malaria parasite. Science (1980) 3.71
Ca++-dependent binding of antigen-19 S antibody complexes to macrophages. J Immunol (1969) 3.70
Release of decay-accelerating factor (DAF) from the cell membrane by phosphatidylinositol-specific phospholipase C (PIPLC). Selective modification of a complement regulatory protein. J Exp Med (1986) 3.68
Studies on the mechanism of solubilization of immune precipitates by serum. J Exp Med (1976) 3.68
Complement receptor is an inhibitor of the complement cascade. J Exp Med (1981) 3.65
Cloning of decay-accelerating factor suggests novel use of splicing to generate two proteins. Nature (1987) 3.62
Unique role of the complement receptor CR1 in the degradation of C3b associated with immune complexes. J Exp Med (1982) 3.42
Distribution of decay-accelerating factor in the peripheral blood of normal individuals and patients with paroxysmal nocturnal hemoglobinuria. J Exp Med (1985) 3.33
Inhibition of development of exoerythrocytic forms of malaria parasites by gamma-interferon. Science (1986) 3.33
Rationale for development of a synthetic vaccine against Plasmodium falciparum malaria. Science (1985) 3.24
Chloroquine-resistant Plasmodium falciparum from East Africa: cultivation and drug sensitivity of the Tanzanian I/CDC strain from an American tourist. Lancet (1979) 3.22
Theta-bearing and complement-receptor lymphocytes are distinct populations of cells. Science (1971) 3.16
Circumsporozoite proteins of malaria parasites contain a single immunodominant region with two or more identical epitopes. J Exp Med (1983) 3.07
Human C4-binding protein. II. Role in proteolysis of C4b by C3b-inactivator. J Exp Med (1978) 2.98
Antibodies to sporozoites: their frequent occurrence in individuals living in an area of hyperendemic malaria. Science (1979) 2.91
Experimental mosquito-transmission of Plasmodium knowlesi to man and monkey. Am J Trop Med Hyg (1968) 2.89
Plasma concentration of LH, FSH, prolactin, progesterone and estradiol-17beta throughout the 4-day estrous cycle of the rat. Endocrinology (1974) 2.87
Identification of the complement decay-accelerating factor (DAF) on epithelium and glandular cells and in body fluids. J Exp Med (1987) 2.86
The basolateral domain of the hepatocyte plasma membrane bears receptors for the circumsporozoite protein of Plasmodium falciparum sporozoites. Cell (1992) 2.78
Monoclonal antibodies to circumsporozoite proteins identify the species of malaria parasite in infected mosquitoes. Nature (1982) 2.76
Modulation of the classical pathway C3 convertase by plasma proteins C4 binding protein and C3b inactivator. Proc Natl Acad Sci U S A (1979) 2.73
CD8+ cytolytic T cell clones derived against the Plasmodium yoelii circumsporozoite protein protect against malaria. Int Immunol (1991) 2.67
Population dynamics of untreated Plasmodium falciparum malaria within the adult human host during the expansion phase of the infection. Parasitology (2002) 2.67
Demonstration of heat-shock protein 70 in the sporozoite stage of malaria parasites. Parasitol Res (1994) 2.65
Rationale for the development of an engineered sporozoite malaria vaccine. Adv Immunol (1989) 2.64
Malaria circumsporozoite protein binds to heparan sulfate proteoglycans associated with the surface membrane of hepatocytes. J Exp Med (1993) 2.60
Structure of the plasmodium knowlesi gene coding for the circumsporozoite protein. Cell (1983) 2.60
Human C4-binding protein. I. Isolation and characterization. J Exp Med (1978) 2.60
Signal for attachment of a phospholipid membrane anchor in decay accelerating factor. Science (1987) 2.59
Cell surface immunoglobulin. IV. Distribution among thymocytes, bone mrrow cells, and their derived populations. J Exp Med (1972) 2.50
Circumsporozoite protein is required for development of malaria sporozoites in mosquitoes. Nature (1997) 2.49
DNA cloning of Plasmodium falciparum circumsporozoite gene: amino acid sequence of repetitive epitope. Science (1984) 2.47
Human lymphocytes bear membrane receptors for C3b and C3d. J Clin Invest (1973) 2.46
Circumsporozoite proteins of malaria parasites. Cell (1985) 2.45
Priming with recombinant influenza virus followed by administration of recombinant vaccinia virus induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl Acad Sci U S A (1993) 2.44
Conservation of a gliding motility and cell invasion machinery in Apicomplexan parasites. J Cell Biol (1999) 2.43
Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science (1985) 2.41
Research toward malaria vaccines. Science (1986) 2.40
The indirect fluorescent antibody test for malaria. Am J Trop Med Hyg (1972) 2.37
Identification of Plasmodium vivax-like human malaria parasite. Lancet (1993) 2.37
Antihapten antibody specificity and L chain type. J Exp Med (1967) 2.33
Further studies on the Plasmodium berghei-Anopheles stephensi--rodent system of mammalian malaria. J Parasitol (1968) 2.32
Identification of the membrane receptor for the complement fragment C3d by means of a monoclonal antibody. J Exp Med (1983) 2.31
Tissue localization of lymphocytes bearing a membrane receptor for antigen-antibody-complement complexes. Proc Natl Acad Sci U S A (1970) 2.29
Complement-dependent release of immune complexes from the lymphocyte membrane. J Exp Med (1973) 2.27
Stage-specific surface antigens expressed during the morphogenesis of vertebrate forms of Trypanosoma cruzi. Exp Parasitol (1987) 2.25
Increased proportion of complement-receptor lymphocytes in the peripheral blood of patients with chronic lymphocytic leukemia. Blood (1972) 2.25
Requirements for the solubilization of immune aggregates by complement. The role of the classical pathway. J Clin Invest (1978) 2.24
Receptors for immune complexes on lymphocytes. Adv Immunol (1974) 2.23
Immunization of Aotus monkeys with recombinant proteins of an erythrocyte surface antigen of Plasmodium falciparum. Nature (1986) 2.19
Interferon-gamma inhibits the intrahepatocytic development of malaria parasites in vitro. J Immunol (1987) 2.19
Inhibition of entry of Plasmodium falciparum and P. vivax sporozoites into cultured cells; an in vitro assay of protective antibodies. J Immunol (1984) 2.18
Ubiquity of the repetitive epitope of the CS protein in different isolates of human malaria parasites. J Immunol (1985) 2.09
Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother (1998) 2.07
Increased nonspecific resstance to malaria produced by administration of killed Corynebacterium parvum. Exp Parasitol (1967) 2.06
A novel cell surface trans-sialidase of Trypanosoma cruzi generates a stage-specific epitope required for invasion of mammalian cells. Cell (1991) 2.04
Anophelines in the state of Acre, Brazil, infected with Plasmodium falciparum, P. vivax, the variant P. vivax VK247 and P. malariae. Trans R Soc Trop Med Hyg (1993) 2.03
Biosynthesis of Pb44, the protective antigen of sporozoites of Plasmodium berghei. J Exp Med (1981) 2.02
Anaemia of acute malaria infections in non-immune patients primarily results from destruction of uninfected erythrocytes. Parasitology (1999) 2.02
Antibody-induced ultrastructural changes of malarial sporozoites. J Immunol (1976) 1.97
The role of C4-binding protein and beta 1H in proteolysis of C4b and C3b. J Exp Med (1979) 1.97
Interferon-gamma responses are associated with resistance to reinfection with Plasmodium falciparum in young African children. J Infect Dis (1999) 1.96